Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab

Neurology

Volumn 76, Issue 8, 2011, Pages 759-760

  Sørensen, Per Soelberg ^a   Koch Henriksen, Nils ^a,b   Jensen, Poul Erik Hyldgaard ^a  

^a University of Copenhagen   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; NATALIZUMAB; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 79952016482     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31820d62a4     Document Type: Article

References (6)

1. Hesse D, Sorensen PS. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. Eur J Neurol 2007;14:850-859. (Pubitemid 47106761)
2. Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67:1681-1683. (Pubitemid 44747946)
3. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-1403. (Pubitemid 47511460)
4. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83:219-227.
5. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191. (Pubitemid 37255344)
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.